

Compounds for Amelioration of Neurodegenerative Diseases

- **TECHNOLOGY:** Neurodegenerative diseases such as Alzheimer's and Parkinson's disease occur as a result of inflammatory insult to neuron-surrounding cells. Traditionally used Levodopa has only seen limited success in arresting or reversing the disease. The current technology comprises a combination therapy comprising a Tyrosine kinase inhibitor and Sirtuin-2 as effective treatment regimen in bringing down the inflammation of neuron- surrounding cells and therefore promises possibilities of a therapeutic intervention in such debilitating neuropathologies.
- **DOMAIN:** Disease Intervention
- **APPLICATIONS:** The mechanism of action promises to be an effective intervention for Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis.
- **ADVANTAGES:** The composition is formulated into a dosage form selected from a group comprising solid oral formulation, liquid formulation and parenteral formulation or combinations thereof. Controlled as well as prolonged release formulations are contemplated.
- **IP STATUS:** US patent-US11324747B2 issued and Indian patent application 201947000685 filed.

Contact us:

OFFICE OF TECHNOLOGY TRANSFER, CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS (C-CAMP). GKVK POST, BELLARY ROAD, BANGALORE 560065, INDIA.

EMAIL: OTT@CCAMP.RES.IN, PH: +918067185322